Pharmacology ATI Proctored Exam 2025/2027 with NGN
Complete Questions Verified Answers and Detailed Rationales
for Nursing Exam Success - 230 Questions and Answers Already
Graded A+ Premium Exam Tested And Verified
Subject Area Pharmacology
Description Comprehensive assessment of advanced pharmacology principles including
pharmacokinetics, pharmacodynamics, drug classifications, and clinical
application across major disease states. Designed to prepare nursing students for
the ATI Proctored Exam and NCLEX-RN, this exam reflects the depth and rigor
of top-tier US nursing programs.
Expected Grade A+
Total Questions 230
Duration 3 hours
Learning Outcomes 1. Apply pharmacokinetic and pharmacodynamic principles to patient-specific
variables
2. Differentiate between drug classes and predict therapeutic and adverse effects
3. Integrate pharmacology knowledge to make safe clinical decisions in complex
scenarios
Accreditation This exam aligns with AACN and QSEN competencies and meets the standards of
Ivy League and R1 research university nursing programs.
Page 1
,1. A partial agonist at a receptor produces a submaximal response even at full
receptor occupancy. If a full agonist is coadministered at a concentration that
alone yields 80% of maximal response, what is the most likely final effect?
Answer: Response decreases below 80% due to competitive antagonism
A partial agonist has lower intrinsic efficacy than a full agonist. When
coadministered, it occupies receptors and prevents full agonist binding, reducing
the overall response below that of the full agonist alone - effectively acting as a
competitive antagonist.
2. A patient with asthma and hypertension requires a beta-blocker. Which
property of beta-blockers would minimize the risk of bronchospasm?
Answer: High beta-1 selectivity with partial beta-2 agonism
Beta-1 selective blockers reduce cardiac effects while sparing beta-2 receptors in
the lungs. Adding partial beta-2 agonism provides some bronchodilation, further
lowering bronchospasm risk. Purely selective blockers (option A) are safer than
nonselective ones but still may cause bronchospasm in severe asthma; partial
agonism offers additional protection.
3. A patient on digoxin presents with nausea, bradycardia, and visual
disturbances. Serum digoxin level is 3.2 ng/mL. The ECG shows atrial
tachycardia with block. Which intervention is most appropriate?
Answer: Administer digoxin immune Fab and correct hypokalemia if present
Digoxin toxicity with life-threatening dysrhythmia requires digoxin immune Fab
for rapid reversal. Hypokalemia worsens toxicity; correcting it is essential.
Atropine may be used for bradycardia but does not address the cause; increasing
digoxin, lidocaine, or diltiazem could exacerbate toxicity.
Page 2
,4. A patient receiving morphine reports severe pain relief but develops
respiratory depression. Administration of naloxone reverses the respiratory
depression but also reduces analgesia. This is primarily due to naloxone's
action on which opioid receptor subtype?
Answer: Mu-2 ()
Mu-2 receptors mediate respiratory depression and gastrointestinal effects, while
mu-1 mediates supraspinal analgesia. Naloxone antagonizes all mu subtypes, but
its reversal of respiratory depression is primarily due to blockade of mu-2. Mu-1
antagonism leads to loss of analgesia.
5. A patient with a deep-seated MRSA infection fails vancomycin therapy
(MIC = 2 g/mL). The prescriber considers daptomycin. Which factor is critical
to monitor during daptomycin therapy?
Answer: Creatine phosphokinase (CPK) due to risk of myopathy
Daptomycin can cause skeletal muscle toxicity, requiring weekly CPK
monitoring. It is not nephrotoxic (unlike vancomycin) and does not significantly
affect INR or blood glucose. Vancomycin failure with MIC>1.5 may indicate
vancomycin-intermediate S. aureus; daptomycin is an alternative but requires
dose adjustment if renal impairment.
6. A patient with HER2-positive metastatic breast cancer is to start
trastuzumab. Which statement accurately describes the mechanism and
monitoring for this therapy?
Answer: Trastuzumab binds to HER2 receptors, and left ventricular ejection
fraction must be monitored due to risk of cardiomyopathy
Trastuzumab is a monoclonal antibody targeting HER2, used in HER2+ breast
cancer. It can cause cardiotoxicity, especially with anthracyclines, so LVEF must
be monitored. Options B, C, and D describe other agents: B is afatinib or similar
TKI, C is bevacizumab, D is anastrozole.
Page 3
, 7. A postoperative patient has a PCA pump with morphine and is receiving
scheduled ibuprofen and acetaminophen. The patient reports persistent pain
(7/10). The nurse considers adding gabapentin. Which principle of multimodal
analgesia does this addition represent?
Answer: Synergistic effect by targeting multiple pain pathways, reducing
opioid dose
Multimodal analgesia combines agents from different classes to target various
pain mediators, achieving additive or synergistic effects. This allows lower doses
of each drug, particularly opioids, reducing side effects. Gabapentin modulates
calcium channels, complementing opioids and NSAIDs. Options B, C, and D are
incorrect: it does not replace opioids completely, uses lower doses, and different
mechanisms.
8. A drug has an oral bioavailability of 25% and is extensively metabolized by
the liver via CYP3A4. If a patient is concurrently administered a potent
CYP3A4 inhibitor, what is the most likely effect on the drug's oral
bioavailability and the required dose adjustment?
Answer: Bioavailability increases; dose reduction is necessary.
A CYP3A4 inhibitor will decrease first-pass metabolism, increasing oral
bioavailability. To avoid toxicity, a dose reduction is typically required. Choices
B, C, and D misinterpret the effect of inhibition on bioavailability and dose
adjustments.
9. A drug acts as a partial agonist at -opioid receptors. Compared to a full
agonist, which statement accurately describes its dose-response relationship
and clinical utility?
Answer: It produces a lower maximal effect and may have a ceiling effect for
analgesia.
Partial agonists have lower intrinsic activity, resulting in a lower maximal effect
(ceiling) compared to full agonists. They are useful where a ceiling effect reduces
abuse potential or respiratory depression. Options A, B, and D are incorrect
regarding maximal effect or potency.
Page 4
Complete Questions Verified Answers and Detailed Rationales
for Nursing Exam Success - 230 Questions and Answers Already
Graded A+ Premium Exam Tested And Verified
Subject Area Pharmacology
Description Comprehensive assessment of advanced pharmacology principles including
pharmacokinetics, pharmacodynamics, drug classifications, and clinical
application across major disease states. Designed to prepare nursing students for
the ATI Proctored Exam and NCLEX-RN, this exam reflects the depth and rigor
of top-tier US nursing programs.
Expected Grade A+
Total Questions 230
Duration 3 hours
Learning Outcomes 1. Apply pharmacokinetic and pharmacodynamic principles to patient-specific
variables
2. Differentiate between drug classes and predict therapeutic and adverse effects
3. Integrate pharmacology knowledge to make safe clinical decisions in complex
scenarios
Accreditation This exam aligns with AACN and QSEN competencies and meets the standards of
Ivy League and R1 research university nursing programs.
Page 1
,1. A partial agonist at a receptor produces a submaximal response even at full
receptor occupancy. If a full agonist is coadministered at a concentration that
alone yields 80% of maximal response, what is the most likely final effect?
Answer: Response decreases below 80% due to competitive antagonism
A partial agonist has lower intrinsic efficacy than a full agonist. When
coadministered, it occupies receptors and prevents full agonist binding, reducing
the overall response below that of the full agonist alone - effectively acting as a
competitive antagonist.
2. A patient with asthma and hypertension requires a beta-blocker. Which
property of beta-blockers would minimize the risk of bronchospasm?
Answer: High beta-1 selectivity with partial beta-2 agonism
Beta-1 selective blockers reduce cardiac effects while sparing beta-2 receptors in
the lungs. Adding partial beta-2 agonism provides some bronchodilation, further
lowering bronchospasm risk. Purely selective blockers (option A) are safer than
nonselective ones but still may cause bronchospasm in severe asthma; partial
agonism offers additional protection.
3. A patient on digoxin presents with nausea, bradycardia, and visual
disturbances. Serum digoxin level is 3.2 ng/mL. The ECG shows atrial
tachycardia with block. Which intervention is most appropriate?
Answer: Administer digoxin immune Fab and correct hypokalemia if present
Digoxin toxicity with life-threatening dysrhythmia requires digoxin immune Fab
for rapid reversal. Hypokalemia worsens toxicity; correcting it is essential.
Atropine may be used for bradycardia but does not address the cause; increasing
digoxin, lidocaine, or diltiazem could exacerbate toxicity.
Page 2
,4. A patient receiving morphine reports severe pain relief but develops
respiratory depression. Administration of naloxone reverses the respiratory
depression but also reduces analgesia. This is primarily due to naloxone's
action on which opioid receptor subtype?
Answer: Mu-2 ()
Mu-2 receptors mediate respiratory depression and gastrointestinal effects, while
mu-1 mediates supraspinal analgesia. Naloxone antagonizes all mu subtypes, but
its reversal of respiratory depression is primarily due to blockade of mu-2. Mu-1
antagonism leads to loss of analgesia.
5. A patient with a deep-seated MRSA infection fails vancomycin therapy
(MIC = 2 g/mL). The prescriber considers daptomycin. Which factor is critical
to monitor during daptomycin therapy?
Answer: Creatine phosphokinase (CPK) due to risk of myopathy
Daptomycin can cause skeletal muscle toxicity, requiring weekly CPK
monitoring. It is not nephrotoxic (unlike vancomycin) and does not significantly
affect INR or blood glucose. Vancomycin failure with MIC>1.5 may indicate
vancomycin-intermediate S. aureus; daptomycin is an alternative but requires
dose adjustment if renal impairment.
6. A patient with HER2-positive metastatic breast cancer is to start
trastuzumab. Which statement accurately describes the mechanism and
monitoring for this therapy?
Answer: Trastuzumab binds to HER2 receptors, and left ventricular ejection
fraction must be monitored due to risk of cardiomyopathy
Trastuzumab is a monoclonal antibody targeting HER2, used in HER2+ breast
cancer. It can cause cardiotoxicity, especially with anthracyclines, so LVEF must
be monitored. Options B, C, and D describe other agents: B is afatinib or similar
TKI, C is bevacizumab, D is anastrozole.
Page 3
, 7. A postoperative patient has a PCA pump with morphine and is receiving
scheduled ibuprofen and acetaminophen. The patient reports persistent pain
(7/10). The nurse considers adding gabapentin. Which principle of multimodal
analgesia does this addition represent?
Answer: Synergistic effect by targeting multiple pain pathways, reducing
opioid dose
Multimodal analgesia combines agents from different classes to target various
pain mediators, achieving additive or synergistic effects. This allows lower doses
of each drug, particularly opioids, reducing side effects. Gabapentin modulates
calcium channels, complementing opioids and NSAIDs. Options B, C, and D are
incorrect: it does not replace opioids completely, uses lower doses, and different
mechanisms.
8. A drug has an oral bioavailability of 25% and is extensively metabolized by
the liver via CYP3A4. If a patient is concurrently administered a potent
CYP3A4 inhibitor, what is the most likely effect on the drug's oral
bioavailability and the required dose adjustment?
Answer: Bioavailability increases; dose reduction is necessary.
A CYP3A4 inhibitor will decrease first-pass metabolism, increasing oral
bioavailability. To avoid toxicity, a dose reduction is typically required. Choices
B, C, and D misinterpret the effect of inhibition on bioavailability and dose
adjustments.
9. A drug acts as a partial agonist at -opioid receptors. Compared to a full
agonist, which statement accurately describes its dose-response relationship
and clinical utility?
Answer: It produces a lower maximal effect and may have a ceiling effect for
analgesia.
Partial agonists have lower intrinsic activity, resulting in a lower maximal effect
(ceiling) compared to full agonists. They are useful where a ceiling effect reduces
abuse potential or respiratory depression. Options A, B, and D are incorrect
regarding maximal effect or potency.
Page 4
